Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Salvatrice Mancuso, Antonella Montanini, Gabriele Buda, Eliana Liardo, Donato Mannina, Alessandra Dondi, Stefania Muci, Caterina Plati, Catia Patti, Renato Cantaffa, Caterina Stelitano, M. Rosaria De Paolis, Nicola Di Renzo, Massimo Federico, Attilio Olivieri, Salvatrice Mancuso

Risultato della ricerca: Article

18 Citazioni (Scopus)

Abstract

PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids.METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0-120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint.RESULTS: Eighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0-24 h) and delayed (24-120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%.CONCLUSIONS: This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin's lymphoma receiving MEC regimen containing steroids.
Lingua originaleEnglish
pagine (da-a)1505-1510
Numero di pagine6
RivistaSupportive Care in Cancer
Volume19(10)
Stato di pubblicazionePublished - 2011

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

Mancuso, S., Montanini, A., Buda, G., Liardo, E., Mannina, D., Dondi, A., Muci, S., Plati, C., Patti, C., Cantaffa, R., Stelitano, C., De Paolis, M. R., Di Renzo, N., Federico, M., Olivieri, A., & Mancuso, S. (2011). Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Supportive Care in Cancer, 19(10), 1505-1510.